The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection
Frontiers in Cellular and Infection Microbiology · 22.01.2024 · 14
DOI: 10.3389/fcimb.2024.1335450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 22.01.2024. Verfasst von Antonia Piazzesi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: COVID-19, Microbiota. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Since the beginning of the SARS-CoV-2 pandemic in early 2020, it has been apparent that children were partially protected from both infection and the more severe forms of the disease. Many different mechanisms have been proposed to explain this phenomenon, including children’s frequent exposure to other upper respiratory infections and vaccines, and which inflammatory cytokines they are more likely to produce in response to infection. Furthermore, given the presence of SARS-CoV-2 in the intestine and its ability to infect enterocytes, combined with the well described immunomodulatory capabilities of the microbiome, another potential contributing factor may be the presence of certain protective microbial members of the gut microbiota (GM).
Methods
We performed shotgun metagenomic sequencing and profiled both the bacteriome and virome of the GM of pediatric SARS-CoV-2 patients compared to healthy, age-matched subjects.
Results
We found that, while pediatric patients do share some pro-inflammatory microbial signatures with adult patients, they also possess a distinct microbial signature of protective bacteria previously found to be negatively correlated with SARS-CoV-2 infectivity and COVID-19 severity. COVID-19 was also associated with higher fecal Cytomegalovirus load, and with shifts in the relative abundances of bacteriophages in the GM. Furthermore, we address how the preventative treatment of COVID-19 patients with antibiotics, a common practice especially in the early days of the pandemic, affected the bacteriome and virome, as well as the abundances of antimicrobial resistance and virulence genes in these patients.
Discussion
To our knowledge, this is the first study to address the bacteriome, virome, and resistome of pediatric patients in response to COVID-19 and to preventative antibiotics use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Unit of Microbiomics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Infectious Diseases Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Zitieren
APA
Piazzesi, A., Pane, S., Del Chierico, F., Romani, L., Campana, A., Palma, P., & Putignani, L. (2024). The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1335450
Vancouver
Piazzesi A, Pane S, Del Chierico F, Romani L, Campana A, Palma P, et al. The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1335450
BibTeX
@article{Piazzesi2024,
author = {Piazzesi, Antonia and Pane, Stefania and Del Chierico, Federica and Romani, Lorenza and Campana, Andrea and Palma, Paolo and Putignani, Lorenza},
title = {The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
volume = {14},
doi = {10.3389/fcimb.2024.1335450}
}
EUVIMED